Callitas Therapeutics Inc (LILY):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Callitas Therapeutics Inc (LILY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9438
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Callitas Therapeutics Inc (Callitas Therapeutics), formerly M Pharmaceutical Inc, is a drug discovery and development company that offers ground-breaking drug treatments and biomedical technologies. The company’s products include weight management products, infertility products and women’s healthcare products. It also provides comprising ToConceive, C-103 Reformulated Orlistat and Extrinsa. Callitas Therapeutics’ products are used to improve the lives of people facing obesity, infertility and intimacy issues. The company’s ToConceive is a fertility enhancing moisturizer that increases woman’s own natural conception lubrication called transudate to aid in conception and Extrinsa address the lack of female sexual dysfunction solutions and focus on women with orgasm and arousal difficulties. Its topical, local, and non-systemic product is also non-hormonal and does not affect the central nervous system. Callitas Therapeutics is headquartered in Vancouver, British Columbia, Canada.

Callitas Therapeutics Inc (LILY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Callitas Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
M Pharma Acquires Assets from 40J’s 12
M Pharma Acquires Orlistat Assets from Chelatexx 13
Partnerships 14
Callitas Health Enters into Partnership with NFI Consumer Healthcare 14
M Pharma to Form Joint Venture 15
Licensing Agreements 16
Callitas Health Recieves Intellectual Property from Ronald J. Thompson 16
M Pharma Enters into Licensing Agreement for Pediatric Orphan Drug 17
Equity Offering 18
M Pharma Raises USD0.03 Million in Private Placement of Units 18
M Pharma Raises USD0.7 Million in Private Placement of Units 19
M Pharma to Raise USD0.3 Million in Private Placement of Units 20
M Pharma Raises USD0.86 Million in Private Placement of Units 21
M Pharma Raises USD1 Million in Private Placement of Units 22
Acquisition 23
M Pharma Acquires ToConceive 23
M Pharma Plans to Acquire Pharma Company with an FDA Approved Women’s Health Product 24
M Pharma Acquires Trimtec Biomedical 25
M Pharma Acquires RX Global Capital for USD1.9 Million 26
Callitas Therapeutics Inc – Key Competitors 27
Callitas Therapeutics Inc – Key Employees 28
Callitas Therapeutics Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Corporate Communications 30
Jun 07, 2018: James Thompson Elevated to President and Chief Executive Officer of Callitas Health 30
Jan 03, 2018: Callitas Announces New Interim CEO 31
Jun 08, 2017: M Pharmaceutical Appoints New Chief Financial Officer 32
Mar 03, 2017: M Pharmaceutical Appoints Kim Whittemore of San Diego, California to Its Board of Directors 33
Feb 21, 2017: M Pharmaceutical Appoints Mr. William A. Rodgers Jr., of Milton, Georgia to Its Board of Directors 34
Feb 13, 2017: M Pharmaceutical Appoints Mr. Gary Thompson President & CEO 35
Product News 36
Sep 29, 2017: ToConceive launches new paraben-free formula to promote natural conception 36
07/14/2017: M Pharmaceutical Provides Update on Extrinsa 37
Jan 24, 2017: M Pharmaceutical Announces Strategy To Seek Distribution Partners For Their Patented Technologies To Deliver Phytoestrogens For The Treatment Of The Symptoms Of Menopause 38
Jan 12, 2017: M Pharmaceutical Announces Plans to Develop a Drug Product for Treatment of Female Sexual Dysfunction 39
Product Approvals 40
Oct 11, 2017: Callitas Announces Positive FDA Response to Extrinsa Pre-IND Submission 40
Jul 18, 2017: M Pharmaceutical Plans to Submit Extrinsa PIND Meeting Request Letter and Package to US FDA 41
Other Significant Developments 42
Apr 19, 2018: Callitas Health Releases Annual Update Letter to Shareholders 42
Mar 13, 2018: Callitas Health Announces Selection Of TraDigitalIR As Investor And Public Relations Advisor 44
Mar 01, 2018: Callitas Health Has Big Plans For Broad Product Portfolio 45
Sep 15, 2017: M Pharmaceutical Announces Name Change to Callitas Health and Share Consolidation 47
Aug 01, 2017: M Pharmaceutical USA Announces a Change of Name to Callitas Therapeutics 48
Jul 07, 2017: M pharmaceutical reforecasts 2017 and 2018 revenues upward 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Callitas Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Callitas Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
M Pharma Acquires Assets from 40J’s 12
M Pharma Acquires Orlistat Assets from Chelatexx 13
Callitas Health Enters into Partnership with NFI Consumer Healthcare 14
M Pharma to Form Joint Venture 15
Callitas Health Recieves Intellectual Property from Ronald J. Thompson 16
M Pharma Enters into Licensing Agreement for Pediatric Orphan Drug 17
M Pharma Raises USD0.03 Million in Private Placement of Units 18
M Pharma Raises USD0.7 Million in Private Placement of Units 19
M Pharma to Raise USD0.3 Million in Private Placement of Units 20
M Pharma Raises USD0.86 Million in Private Placement of Units 21
M Pharma Raises USD1 Million in Private Placement of Units 22
M Pharma Acquires ToConceive 23
M Pharma Plans to Acquire Pharma Company with an FDA Approved Women's Health Product 24
M Pharma Acquires Trimtec Biomedical 25
M Pharma Acquires RX Global Capital for USD1.9 Million 26
Callitas Therapeutics Inc, Key Competitors 27
Callitas Therapeutics Inc, Key Employees 28
Callitas Therapeutics Inc, Subsidiaries 29

List of Figures
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Callitas Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Callitas Therapeutics Inc (LILY):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Illumina, Inc.:企業のM&A・提携・投資分析
    Illumina, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Illumina, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Formosa International Hotels Corporation:企業の戦略・SWOT・財務分析
    SummaryFormosa International Hotels Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of …
  • Synthetic Biologics, Inc. (SYN)(製薬・医療分野):企業M&A動向
    Summary Synthetic Biologics, Inc. (Synthetic Biologics), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company. It undertakes the development of anti-infective biologics and drug candidates targeting infections and disease specific pathogens. The company also develops synthetic biologic …
  • Vascular Concepts Limited:企業の製品パイプライン分析2016
    Summary Vascular Concepts Limited (Vascular Concepts) is a medical device company that designs, develops and manufactures endovascular medical devices for the treatment of arterial diseases. The company offers products including coronary stents, peripheral stents and balloon. Its coronary system inc …
  • Promotora y Operadora de Infraestructura,S.A.B. de C.V.:企業の戦略・SWOT・財務分析
    SummaryPromotora y Operadora de Infraestructura,S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing …
  • Primary Health Properties PLC:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Primary Health Properties PLC M …
  • Universal Forest Products, Inc.:企業の戦略・SWOT・財務分析
    SummaryUniversal Forest Products, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the comp …
  • ITS Group SA (ITS):企業財務及び戦略的SWOT分析
    Summary ITS Group SA (ITS Group) is an information technology company that offers IT based solutions. The company’s services include IT governance, IT production and user services. Its IT governance services comprise capacity management, hyper-vision and supervision services; flate rate and change m …
  • Calytrix Technologies Pty Ltd.:企業の戦略・SWOT・財務情報
    Calytrix Technologies Pty Ltd. - Strategy, SWOT and Corporate Finance Report Summary Calytrix Technologies Pty Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Energias de Portugal SA (EDP)-エネルギー分野:企業M&A・提携分析
    Summary Energias de Portugal, S.A. (EDP) is a vertically integrated power and gas utility that generates, transmits, distributes and sells electricity; and transports, distributes and sells natural gas. It produces electricity through a diversified portfolio of generation assets including wind, sola …
  • HudBay Minerals Inc.:企業のM&A・提携・投資分析
    HudBay Minerals Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HudBay Minerals Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Siamab Therapeutics, Inc.(製薬・医療分野):企業M&A動向
    Summary Siamab Therapeutics, Inc. (Siamab Therapeutics), formerly Sialix, Inc., is a biopharmaceutical company. The company research and develops new cancer immunotherapies for use in the treatment of cancer diseases. Its technology platform supports discovery and development of anti-TACA therapeuti …
  • EnQuest PLC (ENQ):企業のM&A・提携動向(石油・ガス分野)
    Summary EnQuest PLC (EnQuest) is an independent oil and gas exploration and production company. The company’s assets include producing oil fields, new developments and a portfolio of discoveries. Its major assets are located in the UK North Sea. EnQuest also has presence in oil basins outside the UK …
  • Toyo Ink Group Berhad (TOYOINK):企業財務及び戦略的SWOT分析
    Summary Toyo Ink Group Berhad (TIG Ink Group) is a chemical company that manufactures gravure and flexographic printing inks for the packaging industry. The company’s products include gravure ink, flexographic ink, offset ink, varnish, master batch, glasurit and consumable and equipment for graphic …
  • Shin Poong PharmCo Ltd (019170):企業財務及び戦略的SWOT分析
    Summary Shin Poong PharmCo Ltd (Shin Poong) manufactures and markets active pharmaceutical ingredients (APIs) and pharmaceutical products. The company provides cardiovascular, psychoneurotic, anti-cancer, antihistamine, antirheumatic and benign prostatic hyperplasia drugs. It also provides antiulcer …
  • Nordion (Canada) Inc:企業の戦略的SWOT分析
    Nordion (Canada) Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • MphasiS Limited (MPHASIS):企業概要、財務及び戦略的SWOT分析
    Summary MphasiS Limited (MphasiS) is an information technology service provider. The company provides applications services, infrastructure services and business process outsourcing services. Its services include application development, applications management, enterprise application services, tech …
  • deCarta, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' deCarta, Inc. Mergers and Acqui …
  • Zhejiang Sanlux Rubber Co., Ltd. (002224):企業財務及び戦略的SWOT分析
    Summary Zhejiang Sanlux Rubber Co., Ltd. (Sanlux) is a chemical company that develops rubber belts. The company offers products such as classical wrapped V-belts, cogged V-belts and specific transmission V-belts. It provides products including wedge wrapped v-belt, classical wrapped v-belt, banded w …
  • Hamon Research-Cottrell, Inc.:企業の戦略的SWOT分析
    Hamon Research-Cottrell, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆